Publications
174
Citations
2,740
Est. group size
~2
Recurring co-author estimate
Active years
29
Publishing since 1998
Amy L. Dunn's research focuses on inherited bleeding disorders, particularly hemophilia A and B and von Willebrand disease, with an emphasis on clinical trials of new treatments including gene therapy, factor replacement therapies, and prophylactic drug regimens. Her work often involves large multinational clinical trials evaluating safety, efficacy, and quality-of-life outcomes for children and adults with these conditions, as well as developing clinical practice guidelines and imaging protocols for monitoring joint health in hemophilia patients.
Publication output has fluctuated over the last decade, with a notable peak in 2023, but appears to be tapering off in 2025 and 2026 (partial-year data).
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children: XTEND-ed Second Interim Analysis
Hämostaseologie · 2026
- National Bleeding Disorder Foundation Clinical Practice Recommendations for Laboratory Screening of Iron Deficiency With and Without Anemia in the Inherited Bleeding Disorders Population
Haemophilia · 2026
- Efficacy and safety of recombinant von Willebrand factor in on-demand treatment of children with von Willebrand disease: up to 4 years of phase 3/3b follow-up
Research and Practice in Thrombosis and Haemostasis · 2026
- Safety and efficacy of valoctocogene roxaparvovec with prophylactic glucocorticoids: 1-year results from the phase 3b, single-arm, open-label GENEr8-3 study
Journal of Thrombosis and Haemostasis · 2025
- Point-of-care musculoskeletal ultrasound for hemophilic arthropathy: a scoping review of scanning protocols by the Imaging Expert Working Group of the International Prophylaxis Study Group
Research and Practice in Thrombosis and Haemostasis · 2025
- 2169-LB: Comparative Metabolic Effects of Semaglutide, Tirzepatide, and Retatrutide in a Monogenic (db/db) Mouse Model of Obesity
Diabetes · 2025
- 2168-LB: Metabolic and Physiological Effects of Survodutide in Polygenic Type 2 Diabetic Mice (NZO/HILtJ) under Thermoneutral Conditions
Diabetes · 2025
- Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial
Journal of Thrombosis and Haemostasis · 2025
- HTRS2025.P1.8 Efanesoctocog Alfa for the Perioperative Management of Patients With Severe Hemophilia A: 4 Years of Experience in the XTEND Clinical Program in North America
Research and Practice in Thrombosis and Haemostasis · 2025
- Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A
Journal of Thrombosis and Haemostasis · 2024
- Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A
New England Journal of Medicine · 2024
- International Prophylaxis Study Group (IPSG) haemophilia joint MRI scale version 2.0
Haemophilia · 2024
- Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophilia A or B with inhibitors
Haemophilia · 2024
- Hemophilia B
Elsevier eBooks · 2024
- List of Contributors
Elsevier eBooks · 2024
- Haemophilia×20
- Blood×19
- Research and Practice in Thrombosis and Haemostasis×12
- Elsevier eBooks×10
- Journal of Thrombosis and Haemostasis×8
- Jessica H. Lewis
Medicine · The Ohio State University
- Radosław Kaczmarek
Medicine · Indiana University
- Riten Kumar
Medicine · The Ohio State University
- Sarah H. O’Brien
Medicine · The Ohio State University
- Kerry Hege
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile